HELP · Helus Pharma Inc.
What's happening
- HELP is down 17.64% today, trading at $8.71. — Live quote
- Volume today (120,584) is running 5.5x its 3-month average. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 9 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.91 actual vs. $-0.72 estimated (-27.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-11-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-10-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +46.8%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HELP
No accessible free API for these — links go to the source directly.
Financials
Institutional holders
SEC Form 13F filers holding HELP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 3,851,654 | $25.5M | 11.07% | +0.0% | 2026-08-14 |
| ORBIMED ADVISORS LLC | 3,271,400 | $21.6M | 9.40% | -14.6% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,060,000 | $20.2M | 8.79% | +337.1% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 2,632,156 | $17.4M | 7.56% | +9.0% | 2026-08-14 |
| Rosalind Advisors, Inc. | 1,956,814 | $12.9M | 5.62% | +27.7% | 2026-08-14 |
| SPHERA FUNDS MANAGEMENT LTD. | 1,620,753 | $10.7M | 4.66% | +64.2% | 2026-08-14 |
| ACORN CAPITAL ADVISORS, LLC | 1,540,266 | $10.2M | 4.43% | +0.0% | 2026-08-14 |
| DCF Advisers, LLC | 1,434,988 | $9.5M | 4.12% | +107.4% | 2026-08-10 |
| Sio Capital Management, LLC | 1,300,000 | $8.6M | 3.74% | +0.0% | 2026-07-15 |
| Nan Fung Group Holdings Ltd | 987,222 | $6.5M | 2.84% | +114.6% | 2026-08-13 |
| Boxer Capital Management, LLC | 790,000 | $5.2M | 2.27% | +23.4% | 2026-08-14 |
| Logos Global Management LP | 750,000 | $5.0M | 2.15% | +0.0% | 2026-08-14 |
| CITADEL ADVISORS LLC | 620,959 | $4.1M | 1.78% | -29.2% | 2026-08-14 |
| DAFNA Capital Management LLC | 514,061 | $3.4M | 1.48% | +3.2% | 2026-08-14 |
| Walleye Capital LLC | 502,554 | $3.3M | 1.44% | +0.0% | 2026-07-30 |
| Morgan Stanley | 461,886 | $3.1M | 1.33% | -55.0% | 2026-08-11 |
| Knott David M Jr | 370,000 | $2.4M | 1.06% | +5.7% | 2026-08-12 |
| Bank Of America Corp /De/ | 337,435 | $2.2M | 0.97% | +0.0% | 2026-08-14 |
| Stonepine Capital Management, LLC | 330,530 | $965.8K | 0.95% | +146.6% | 2026-08-14 |
| AdvisorShares Investments LLC | 292,711 | $1.9M | 0.84% | +49.6% | 2026-08-11 |
| JANE STREET GROUP, LLC | 280,903 | $1.9M | 0.81% | +164.1% | 2026-08-14 |
| Jpmorgan Chase & Co | 237,828 | $1.6M | 0.68% | +10498.4% | 2026-08-12 |
| ROYCE & ASSOCIATES LP | 232,078 | $1.5M | 0.67% | +49.7% | 2026-08-14 |
| UBS Group AG | 218,726 | $1.4M | 0.63% | -8.2% | 2026-08-13 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 204,424 | $1.4M | 0.59% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 11 most recent filings · covers 2026-08-31 to 2026-09-30
Recent transactions
- Insiders have net bought 788,000 shares over the last 182 days, across 9 purchases and 0 sales.
- Most recent: So Eric H. L. (Reporting person) — Grant / award of 248,000 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| So Eric H. L. | Reporting person | Grant / award | 2026-09-30 | 248,000 |
| Glavine Paul | Chief Growth Officer | Grant / award | 2026-09-30 | 248,000 |
| Cavers Greg | Chief Financial Officer | Open market purchase | 2026-09-29 | 3,000 |
| Halstead Michael | Chief Executive Officer | Open market purchase | 2026-09-21 | 100,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | So Eric H. L. | Reporting person | Grant / award | 248,000 | — |
| 2026-09-30 | Glavine Paul | Chief Growth Officer | Grant / award | 248,000 | — |
| 2026-09-29 | Cavers Greg | Chief Financial Officer | Open market purchase | 3,000 | $12.91 |
| 2026-09-21 | Halstead Michael | Chief Executive Officer | Open market purchase | 100,000 | $13.47 |
| 2026-09-08 | Glavine Paul | Chief Growth Officer | Open market purchase | 100,000 | $12.47 |
| 2026-09-08 | Glavine Paul | Chief Growth Officer | Open market purchase | 100,000 | $12.47 |
| 2026-09-08 | So Eric H. L. | Executive Chair | Open market purchase | 100,000 | $12.39 |
| 2026-09-04 | So Eric H. L. | Executive Chair | Open market purchase | 100,000 | $12.09 |
| 2026-09-03 | Glavine Paul | Chief Growth Officer | Open market purchase | 100,000 | $11.78 |
| 2026-09-01 | So Eric H. L. | Executive Chair | Open market purchase | 95,000 | $11.80 |
| 2026-08-31 | Glavine Paul | Chief Growth Officer | Open market purchase | 90,000 | $11.59 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-11-02 19:45 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-21 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-08-31 | View on SEC.gov → |
Recent news
Headlines about HELP (Helus Pharma Inc.). Links open the publisher — we don’t host full articles.
-
$HELP stock is down 20% today. Here's what we see in our data.
Quiver Quantitative · 2026-11-02 -
TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
PRLog · 2026-11-02 -
Cybin (NASDAQ:HELP) Stock Price Down 6.6% - Here's What Happened
MarketBeat · 2026-11-02 -
Helus Pharma Founders Hand Over the Reins as Investors Weigh a 2026 Depression Readout - ad-hoc-news.de
ad-hoc-news.de · 2026-11-02 -
Nancy Guthrie Case Latest Update Today: Savannah Guthrie Shares Emotional Message, Family Renews Plea for Help; FBI Investigates DNA Evidence in Florida
The Sunday Guardian · 2026-11-02 -
Ben Shelton shares aim of becoming 'better claycourter' with help of Carlos Alcaraz’s former mentor
Sky Sports · 2026-11-02 -
Do Democrats Help Or Hurt SpaceX Stock At $135?
Yahoo Finance · 2026-11-02 -
Mark Cuban’s Proposal: How Stock for Employees Could Help Narrow the Wealth Gap
شبكة تواصل الإخبارية · 2026-11-02
No headlines in this category right now — try “All”.